ZA201404518B - Heterocyclic inhibitors of glutaminase - Google Patents

Heterocyclic inhibitors of glutaminase

Info

Publication number
ZA201404518B
ZA201404518B ZA2014/04518A ZA201404518A ZA201404518B ZA 201404518 B ZA201404518 B ZA 201404518B ZA 2014/04518 A ZA2014/04518 A ZA 2014/04518A ZA 201404518 A ZA201404518 A ZA 201404518A ZA 201404518 B ZA201404518 B ZA 201404518B
Authority
ZA
South Africa
Prior art keywords
glutaminase
heterocyclic inhibitors
heterocyclic
inhibitors
Prior art date
Application number
ZA2014/04518A
Other languages
English (en)
Inventor
Eric Brian Sjogren
Guy Laidig
Lijing Chen
Timothy Friend Stanton
Bindu Goyal
Jim Li
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of ZA201404518B publication Critical patent/ZA201404518B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2014/04518A 2011-11-21 2014-06-19 Heterocyclic inhibitors of glutaminase ZA201404518B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161562266P 2011-11-21 2011-11-21
US201261665370P 2012-06-28 2012-06-28
US201261727195P 2012-11-16 2012-11-16
PCT/US2012/065816 WO2013078123A1 (en) 2011-11-21 2012-11-19 Heterocyclic inhibitors of glutaminase

Publications (1)

Publication Number Publication Date
ZA201404518B true ZA201404518B (en) 2017-04-26

Family

ID=48470227

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2014/04518A ZA201404518B (en) 2011-11-21 2014-06-19 Heterocyclic inhibitors of glutaminase
ZA2016/01655A ZA201601655B (en) 2011-11-21 2016-03-10 Heterocyclic inhibitors of glutaminase

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2016/01655A ZA201601655B (en) 2011-11-21 2016-03-10 Heterocyclic inhibitors of glutaminase

Country Status (26)

Country Link
EP (2) EP2782570B1 (enExample)
JP (3) JP6031527B2 (enExample)
KR (2) KR20190127971A (enExample)
CN (2) CN108785305B (enExample)
AR (1) AR090398A1 (enExample)
AU (1) AU2012340866B2 (enExample)
BR (1) BR112014012129A8 (enExample)
CA (1) CA2856386C (enExample)
CY (1) CY1122707T1 (enExample)
DK (1) DK2782570T3 (enExample)
EA (2) EA026656B1 (enExample)
ES (1) ES2761866T3 (enExample)
HR (1) HRP20192144T1 (enExample)
HU (1) HUE047642T2 (enExample)
IL (2) IL232665A0 (enExample)
LT (1) LT2782570T (enExample)
MX (1) MX362550B (enExample)
PL (1) PL2782570T3 (enExample)
PT (1) PT2782570T (enExample)
RS (1) RS59705B1 (enExample)
SG (2) SG11201402305WA (enExample)
SI (1) SI2782570T1 (enExample)
SM (1) SMT201900738T1 (enExample)
TW (1) TWI585084B (enExample)
WO (1) WO2013078123A1 (enExample)
ZA (2) ZA201404518B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2014043633A1 (en) 2012-09-17 2014-03-20 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
US10793535B2 (en) * 2012-11-16 2020-10-06 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
EA029531B1 (ru) * 2012-11-21 2018-04-30 Аджиос Фармасьютикалз, Инк. Соединения, ингибирующие глутаминазу, и содержащие эти соединения фармацевтические композиции и их применение
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CN105283182A (zh) * 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症
US9457016B2 (en) 2013-08-29 2016-10-04 New York University Methods for treating polycystic kidney disease
WO2015061432A1 (en) * 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
KR20220013017A (ko) * 2014-01-06 2022-02-04 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제 저해제
CN103880777B (zh) * 2014-03-06 2015-12-30 陕西科技大学 一种制备双噻二唑二胺的方法
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN106231900B (zh) * 2014-03-21 2019-05-28 阿吉奥斯制药公司 化合物及其使用方法
AU2015254943B2 (en) * 2014-04-30 2019-04-04 Pfizer Inc. Cycloalkyl-linked diheterocycle derivatives
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
WO2015192014A1 (en) * 2014-06-13 2015-12-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
JP6619758B2 (ja) * 2014-07-03 2019-12-11 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患を処置するためのｇｌｓ１阻害薬
US10660861B2 (en) 2014-07-09 2020-05-26 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
SG11201700816YA (en) 2014-08-07 2017-02-27 Calithera Biosciences Inc Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
EA037152B1 (ru) * 2015-03-30 2021-02-11 Калитера Байосайенсиз, Инк. Способ лечения рака
JP6944377B2 (ja) * 2015-04-06 2021-10-06 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼの阻害剤を用いる肺がんの処置
CA2990457C (en) 2015-06-30 2024-07-02 Board Of Regents, University Of Texas System PYRROLIDINYL AND PIPERIDINYL DERIVATIVES AND RELATED PHARMACEUTICAL COMPOSITIONS USEFUL AS GLS1 INHIBITORS
JP6971239B2 (ja) * 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) * 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201730188A (zh) * 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
JP6976248B2 (ja) 2015-12-22 2021-12-08 ボード オブ リージェンツ、ザ ユニバーシテイ オブ テキサス システム （ｒ）−１−（４−（６−（２−（４−（３，３−ジフルオロシクロブトキシ）−６−メチルピリジン−２−イル）アセトアミド）ピリダジン−３−イル）−２−フルオロブチル）−ｎ−メチル−１ｈ−１，２，３−トリアゾール−４−カルボキサミドの塩形態および多形体
MX2019002108A (es) 2016-08-25 2019-07-08 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
US10195197B2 (en) 2016-08-25 2019-02-05 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
EP3576726A1 (en) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
CN107137401A (zh) * 2017-03-28 2017-09-08 刘纪君 一种治疗产后抑郁症的药物组合物
CN106860460B (zh) * 2017-03-29 2019-04-23 上海市第一人民医院 谷氨酰胺酶抑制剂cb-839在制备治疗雌激素敏感型子宫内膜癌的药物中的应用
US11254666B2 (en) 2017-06-13 2022-02-22 Medshine Discovery Inc. Compound as GLS1 inhibitor
CN111225903B (zh) 2017-10-18 2024-08-16 德州大学系统董事会 谷氨酰胺酶抑制剂疗法
PT3868758T (pt) * 2018-10-16 2023-02-16 Medshine Discovery Inc Derivados de tiadiazole e sua utilização como inibidores gls1 de para o tratamento de cancro
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
KR102649592B1 (ko) * 2021-08-18 2024-03-20 한국화학연구원 신규한 마크로사이클 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
CN116023375A (zh) * 2021-10-25 2023-04-28 成都苑东生物制药股份有限公司 一种杂环类衍生物、其制备方法及用途
US12337274B2 (en) 2022-07-01 2025-06-24 Saudi Arabian Oil Company Methods for absorption and desorption of carbon dioxide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2296080C (en) 1997-07-29 2005-02-01 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
WO1999009825A1 (en) 1997-08-29 1999-03-04 Elan Pharmaceuticals, Inc. Method of preventing neuronal death
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
AU2004263149B2 (en) 2003-08-07 2010-08-19 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP5561702B2 (ja) * 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド Ｐｉ３キナーゼ調節剤および使用方法
AU2009228648B2 (en) 2008-03-27 2013-07-11 Grunenthal Gmbh Substituted cyclohexyldiamines
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy

Also Published As

Publication number Publication date
JP6329226B2 (ja) 2018-05-23
CN108785305B (zh) 2021-10-29
HK1204768A1 (en) 2015-12-04
KR20190127971A (ko) 2019-11-13
EP2782570A1 (en) 2014-10-01
KR20150000866A (ko) 2015-01-05
ZA201601655B (en) 2017-06-28
CN104220070B (zh) 2020-01-21
SI2782570T1 (sl) 2020-02-28
EP2782570A4 (en) 2015-05-27
JP2018111729A (ja) 2018-07-19
EA201491012A1 (ru) 2014-12-30
BR112014012129A8 (pt) 2017-06-20
AR090398A1 (es) 2014-11-12
AU2012340866B2 (en) 2017-03-16
MX2014005928A (es) 2014-08-27
AU2012340866A1 (en) 2014-06-26
JP6031527B2 (ja) 2016-11-24
MX362550B (es) 2019-01-24
CA2856386C (en) 2022-05-31
IL259958B (en) 2021-06-30
TW201329071A (zh) 2013-07-16
EP3620162A1 (en) 2020-03-11
HRP20192144T1 (hr) 2020-02-21
BR112014012129A2 (pt) 2017-06-13
WO2013078123A1 (en) 2013-05-30
IL232665A0 (en) 2014-07-31
DK2782570T3 (da) 2019-12-09
SG10201607685SA (en) 2016-11-29
CY1122707T1 (el) 2021-03-12
JP6577623B2 (ja) 2019-09-18
CN104220070A (zh) 2014-12-17
JP2016210810A (ja) 2016-12-15
JP2014533699A (ja) 2014-12-15
EA026656B1 (ru) 2017-05-31
NZ625913A (en) 2015-12-24
HUE047642T2 (hu) 2020-05-28
SG11201402305WA (en) 2014-06-27
CA2856386A1 (en) 2013-05-30
EA201692166A1 (ru) 2017-07-31
TWI585084B (zh) 2017-06-01
SMT201900738T1 (it) 2020-01-14
LT2782570T (lt) 2020-01-10
RS59705B1 (sr) 2020-01-31
ES2761866T3 (es) 2020-05-21
KR102042290B1 (ko) 2019-11-07
IL259958A (en) 2018-07-31
EP2782570B1 (en) 2019-09-18
CN108785305A (zh) 2018-11-13
PL2782570T3 (pl) 2020-04-30
PT2782570T (pt) 2019-12-17

Similar Documents

Publication Publication Date Title
IL259958B (en) Heterocyclic glutaminase inhibitors
ZA201606590B (en) Heterocyclic glutaminase inhibitors
IL232358A0 (en) Inhibitors of phosphodiesterase type 10a
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
AP4029A (en) Inhibitors of beta-secretase
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
AP2015008389A0 (en) Inhibitors of histone demethylases
SG10201601023UA (en) Inhibitors of nedd8-activating enzyme
IL236963A0 (en) beta-secretase inhibitors
IL232170A0 (en) Heterocyclic carboxamides are useful as phosphodiesterase type 10a inhibitors
EP2755663A4 (en) MicroRNA Inhibitors